The determinants of protective CD8 + memory T cell (CD8 + T M ) immunity remain incompletely defined and may in fact constitute an evolving agency as aging CD8 + T M progressively acquire enhanced rather than impaired recall capacities. Here, we show that old as compared to young antiviral CD8 + T M more effectively harness disparate molecular processes (cytokine signaling, trafficking, effector functions, and costimulation/inhibition) that in concert confer greater secondary reactivity. The relative reliance on these pathways is contingent on the nature of the secondary challenge (greater for chronic than acute viral infections) and over time, aging CD8 + T M re-establish a dependence on the same accessory signals required for effective priming of naïve CD8 + T cells in the first place. Thus, our findings are consistent with the recently proposed "rebound model" that stipulates a gradual alignment of naïve and CD8 + T M properties, and identify a diversified collection of potential targets that may be exploited for the therapeutic modulation of CD8 + T M immunity.
INTRODUCTION
What does it take for pathogen-specific CD8 + memory T cells (CD8 + T M ) to mount an efficient and protective recall response? In most general terms, the efficacy of a secondary (II o ) CD8 + effector T cell (CD8 + T E ) response is contingent on the numbers of available CD8 + T M , their differentiation status and anatomical distribution, the contribution of other immune cell populations (e.g., CD4 + T cells, B cells, innate immune cells), and the precise conditions of pathogen re-encounter, i.e. the nature of the pathogen as well as the route and dosage of infection. Thus, the specific constraints of experimental or naturally occurring pathogen exposure will dictate relevant outcomes that are predictable only in as much as the relative contribution of individual biological parameters are sufficiently understood, a task much complicated by the considerable combinatorial possibilities that ultimately shape the balance of pathogen replication and control, pathogen-induced damage, immunopathology, tissue protection and repair. Simply put, CD8 + T Mmediated immune protection is eminently context-dependent.
The difficulties associated with attempts to define more generally applicable rules for the phenomenon of protective CD8 + T M immunity are perhaps best illustrated by the "effector/central memory T cell" paradigm (T EM and T CM , respectively) that constitutes one of the most widely employed and consequential distinctions in the field of memory T cell research [1] . The analytical and physical separation according to CD62L (and CCR7) expression status has spawned an extraordinary amount of work that has assigned numerous distinctive, and at times seemingly contradictory, properties to CD62L lo CD8 + T EM and CD62L hi CD8 + T CM subsets [2] [3] [4] . The CD8 + T M populations thus defined, however, are very much a moving target. For example, CD62L expression by peripheral CD8 + T M generated in response to an acute pathogen challenge is progressively enhanced as a function of original priming conditions and infection history; upon entry into certain lymphoid or nonlymphoid tissues, CD8 + T M -expressed CD62L is reduced; and CD8 + T EM and T CM subsets themselves are subject to a gradual adaptation that introduces an array of molecular, phenotypic and functional changes including, importantly, an increase of their respective recall capacities [2, [5] [6] [7] [8] [9] [10] . Most recently, D. Busch's group used an elegant serial adoptive transfer system in which single I o , II o or III o L.
monocytogenes-(LM-) specific CD8 + T CM (i.e., CD8 + T CM established after a I o , II o or III o LM challenge) gave rise to recall responses of comparable size, phenotypic and functional diversity, and protective capacity [11, 12] . Since single CD8 + T EM failed to mount a similar response, these studies provide definitive proof that the CD62L hi CD8 + T CM subset harbors greater recall potential [11, 12] yet CD62L itself is apparently dispensable for an effective LM-specific recall response [13] . In some other model systems, enhanced protection was even afforded by CD8 + T EM , their limited proliferative potential notwithstanding [2] [3] [4] . It is therefore imperative to define, beyond the T EM /T CM paradigm, which exact mechanisms contribute to the regulation of effective CD8 + T M recall activity under varied experimental conditions, and to what extent specific molecular pathways may become a dominant force in a given model system. A synthesis of such efforts may then provide a foundation for the formulation of more general rules of CD8 + T M engagement.
In the present work, we took advantage of our observation that aging CD8 + T M specific for lymphocytic choriomeningitis virus (LCMV) gradually acquire unique molecular, phenotypic and functional signatures that are associated with a capacity for more vigorous II o CD8 + T E responses and improved immune protection [9] .
We have further organized these dynamic changes in the "rebound model" of extended CD8 + T M maturation according to which pertinent properties of aging CD8 + T M are progressively aligned, perhaps surprisingly, with those of naïve CD8 + T N populations [9, 10] . Here, by focusing on a diverse set of co-stimulatory and inhibitory, cytokine, chemokine and homing receptors/ligands differentially expressed by old and young CD8 + T M as well as their distinct effector function profiles [9] , we identified a broad array of mechanisms that "tune" CD8 + T M recall reactivity to an acute and/or chronic viral re-challenge, and that specifically support the greater II o CD8 + T E expansions of aged CD8 + T M populations. In particular, we propose that aging CD8 + T M reacquire a dependence on multiple accessory pathways for optimization of their II o CD8 + T E reactivity that were essential for the effective and efficient priming of naïve CD8 + T N in the first place.
RESULTS

Interrogating CD8 + T M recall responses: the mixed adoptive transfer/re-challenge (AT/RC) system.
To identify the mechanisms regulating the differential recall reactivity of young and old antiviral CD8 + T M , we employed a mixed "adoptive transfer/re-challenge" (AT/RC) system described in ref. [9] . In brief, cohorts of young adult mice congenic at the CD45 or CD90 locus were challenged with LCMV (2x10 5 pfu LCMV Armstrong [Arm] i.p.) and allowed to establish LCMV-specific CD8 + T cell memory. By performing viral infections in a staggered fashion, we generated groups of young (~2 months after challenge) and aged (>15 months after infection) LCMV-immune mice that served as donors for a concurrent interrogation of young and old CD8 + T cell memory. As detailed in ref. [9] , the mixed AT/RC model offers several practical advantages that facilitate the elucidation of molecular mechanisms in control of differential CD8 + T M recall capacities. ; Fig.1A) . 5 ., the use of two different re-challenge protocols may differentiate between basic determinants required for CD8 + T M recall responses in the wake of an "acute" LCMV Arm infection (AT/RC Arm) and a more complex constellation of mechanisms supporting the effective coordination II o CD8 + T E expansions after a "chronic" LCMV clone 13 infection (AT/RC cl13) ( Fig.1A) . Altogether, we deployed the mixed AT/RC approach to ascertain the contribution of particular molecular pathways to the divergent II o expansion of young and old CD8 + T M by treatment of recipients with blocking antibodies or use of immunodeficient hosts (Fig.1A) ; while the systemic nature of these interventions cannot discern between direct and indirect effects exerted on CD8 + T cell populations, the broad utility and practical relevance of our approach lies in the relative ease with which CD8 + T E cell responses can be reliably manipulated. Lastly, for facilitated manipulation of CD8 + T M we employed the "p14 chimera" model in which purified naïve and congenic p14 T N (TCRtg CD8 + T cells specific for LCMV glycoprotein GP [33] [34] [35] [36] [37] [38] [39] [40] [41] ) are transferred into B6 recipients that are subsequently challenged with LCMV Arm to generate young and old p14 T M [9] (since p14 T M are a clonotypic population, p14 chimeras also effectively control for TCR affinity/avidity as a potentially confounding variable).
No role for IL-7 and IL-15 in the differential regulation of young and old II o CD8 + T E expansions.
The cytokines IL-7 and IL-15 are essential for the preservation of CD8 + T cell memory as they support homeostatic proliferation and survival of CD8 + T M [14] . Accordingly, the pronounced upregulation of IL-7 and IL-15 receptor components (CD127/IL-7Ra and CD122/IL-2Rb) by aging CD8 + T M suggested their increasing responsiveness to IL-7 and IL-15 (ref. [9] and Fig.S1 which stratifies an enrichment of JAK-STAT pathway genes in old p14 T M ). Although this is indeed the case (determined at the level of cytokine-induced STAT5 phosphorylation), homeostatic proliferation rates of antiviral CD8 + T M remained surprisingly unaffected by age [10] . Nevertheless, enhanced CD8 + T M expression of CD127 and CD122 could still contribute to improved recall responses since both IL-7 and IL-15 may act as "adjuvants" to boost CD8 + T E immunity [15, 16] , albeit in a potentially STAT5-independent manner for II o CD8 + T E responses [17] . We therefore employed the mixed AT/RC system ( Fig.1A) to evaluate the impact of combined IL-7/IL-7Ra blockade on the II o reactivity of young and old CD8 + T M . As shown in Fig.1B , both differential and overall II o CD8 + T E expansions after an "acute" LCMV Arm challenge were impervious to IL-7/IL-7Ra blockade; the data also illustrate that an analysis of different tissues (blood or spleen) and the use of different denominators (II o CD8 + T E per 10 6 cells or total spleen cells) provides essentially similar results ( Fig.1B) . Similarly, IL-7/IL-7Ra blockade remained without consequences in additional mixed AT/RC experiments using the "chronic" LCMV cl13 model (Fig.1C ). Our results further exclude a relevant contribution of thymic stromal lymphopoietin (TSLP) to II o CD8 + T E expansions since the TSLP receptor (TSLPR), downregulated by aging CD8 + T M ( Fig.S1 and ref. [9] ), associates with CD127 for effective signal transduction [18] , and the CD127-specific A7R34 antibody used in our experiments also inhibits TSLP action [19] .
We also ascertained a potential role for IL-15 in our model system by conducting mixed AT/RC experiments with IL-15 -/recipients. Lack of IL-15, however, did not compromise the greater II o reactivity of old CD8 + T M (Fig.1D ); in fact, recall responses of aged CD8 + T M were somewhat increased in IL-15 -/as compared to B6 control mice (2.4-fold, p=0.01; Fig.1D ), perhaps as a result of lymphopenia-enhanced, IL-15-independent expansions in the context of an active inflammation. We conclude that elevated CD127 and CD122 expression by aging CD8 + T M does not improve their recall responses.
Divergent requirements of IL-4, IL-6 and TGFβ for enhanced II o reactivity of aged CD8 + T M .
The dynamic regulation of CD127 and CD122 expression discussed above constitutes a common theme shared by multiple other CD8 + T M -expressed cytokine receptors. With the notable exception of TSLPR, these receptors are all subject to increasing expression by aging CD8 + T M with overall gains varying from the modest (CD126/IL-6Ra, CD130/IL-6ST, IL-21R, IFNAR1) to the more pronounced (CD124/IL-4Ra, TGFβRII, CD119/IFNγR1) ( Fig.S1 and ref. [9] ). Corresponding temporal analyses extended here to bloodborne CD8 + T M populations with different LCMV specificities further support the conclusion that the prolonged phenotypic CD8 + T M maturation is indeed a generalized and systemic phenomenon ( Figs.2A/B & S2) . The kinetics of CD124, CD126 and TGFβRII expression are of particular interest since the signaling pathways downstream of these receptors emerged as distinctive traits in our earlier Ingenuity Pathway Analyses of aging CD8 + T M [9] , and both IL-6 and TGFβ have been suggested to exert crucial roles in the natural history of chronic LCMV infection [20, 21] . To further assess the relation between cytokine receptor expression levels and signal transduction capacity, we briefly exposed young and old p14 T M in vitro to IL-4 or IL-6 and quantified phosphorylation of STAT6 and STAT3, respectively. Here, aged p14 T M indeed responded with greater STAT phosphorylation, and the re-expression of CD124 by old p14 T M at levels otherwise found only on naïve CD8 + T cells correlated with equal IL-4 reactivity of these populations (Fig.2B ). The generally lower CD126 (and CD130 [9] ) expression by CD8 + T M , which required overall higher cytokine concentrations for effective STAT phosphorylation as compared to the IL-4 experiments, nevertheless conferred an age- ). Collectively, these findings add to an emerging consensus about the importance of IL-4 for the generation of effective antiviral CD8 + T cell immunity [22, 23] and demonstrate a specific requirement for IL-4 to support the greater II o reactivity of aged CD8 + T M ; the direct correlation between CD124 expression levels of CD8 + T M and their recall potential as well as the comparable reduction of I o and old II o CD8 + T E expansions in IL-4 -/mice are further consistent with predictions of the "rebound model" that a progressive alignment of CD8 + T N and aging CD8 + T M properties may translate into a reliance on similar co-stimulatory requirements [9] .
IL-6 is among the most prominent cytokines induced after an LCMV infection [24] but despite the enhanced responsiveness of aged CD8 + T M to IL-6 stimulation ( Fig.2B) , the differential II o responses of transferred young and old CD8 + T M were not compromised by an LCMV Arm challenge of IL-6 -/recipients ( Fig.2C ). Using the LCMV cl13 infection protocol, IL-6-deficiency imparted a very modest 1.5-fold reduction of aged but not young II o CD8 + T E expansions that also mirrored a 1.4-fold decrease of the I o response;
neither finding, however, proved significant ( Fig.2D and not shown) suggesting an overall more limited contribution of IL-6 to differential young and old CD8 + T M recall immunity. As to the potential function of TGFβ and related cytokines in the context of CD8 + T M aging, we earlier noted a series of marked transcriptional adaptations (increasing mRNA abundance for activin and BMP receptors as well as Smad1) and further identified a pronounced increase of TGFβRII protein (but not mRNA) expression by aging CD8 + T M (Figs.2B, S2 and ref. [9] [25, 26] , and in agreement with those studies we did not observe an unleashing of old II o CD8 + T E immunity in our mixed AT/RC system following TGFβ blockade, nor could we discern any impact on the CD8 + T M recall responses at large in either acute or chronic infection models ( Fig.2E ).
Contributions of IFNγ, IFNγ receptor and FasL to the differential regulation of CD8 + T M recall responses.
In addition to multiple phenotypic alterations, aging of CD8 + T M also introduces a number of changes among their functional properties that collectively foster a more diversified spectrum of effector activities [9] .
Notably, old CD8 + T M produce more IFNγ on a per cell basis, and a greater fraction of aged CD8 + T M can be induced to express Fas ligand (FasL) [9] . Together with IL-2, the production capacity of which modestly increases with age [9, 27] , IFNγ and FasL also share the distinction as the only CD8 + T M effector molecules whose cognate receptors (CD122, CD119 and CD95/Fas, respectively) are concurrently upregulated by aging CD8 + T M ( Fig.S1 and refs. [9, 10] ). This can have direct implications for the autocrine regulation of CD8 + T M immunity in the context of recall responses as documented for IL-2 [28] , and similar considerations may also apply to IFNγ given that its direct action on CD8 + T cells is required for optimal I o CD8 + T E expansions and CD8 + T M development [29] . If CD8 + T M -intrinsic interactions between FasL and Fas shape II o CD8 + T E immunity, however, remains elusive.
To correlate the differential CD119 expression by young and old CD8 + T M , confirmed and extended here to different LCMV-specific CD8 + T M populations in peripheral blood (Figs.3A & S2), with a direct responsiveness to IFNγ action, we determined the extent of STAT1 phosphorylation in young and old p14 T M . Interestingly, aged p14 T M featured a slight yet significant elevation of constitutive STAT1 phosphorylation, a difference that was further amplified by in vitro exposure to IFNγ (Fig.3A) . Thus, taking into account differential CD119 expression levels, responsiveness to IFNγ, and IFNγ production capacities of young and old CD8 + T M [9] , we conducted a first set of mixed AT/RC experiments with IFNγ -/recipients. In this system, IFNγ production is restricted to the transferred CD8 + T M populations but both host cells and donor CD8 + T M can readily respond to IFNγ. Comparing CD8 + T M recall responses in LCMV Arm-infected B6
vs. IFNγ -/recipients, we found that absence of host IFNγ modestly compromised the II o expansions of both young and old CD8 + T M , though unexpectedly the relative decrease was more pronounced for the former rather than the latter population ( Fig.3B ). We therefore extended our experiments to assess the contribution of IFNγ at large by use of a neutralizing antibody. Here, complete IFNγ blockade further reduced II o CD8 + T E responses and in particular impaired the II o response of aged CD8 + T E (Fig.3B .3C) .
In contrast to IFNγ, the role of FasL:Fas interactions in the LCMV model appears more limited -both [34] , or perhaps the autocrine binding of secreted FasL that, akin to a mechanism proposed for tumor cells [35] , may shield II o CD8 + T E from FasL-mediated fratricide.
LFA-1 and CXCR3 blockade preferentially curtail II o expansions of aged CD8 + T M .
Among the array of phenotypic changes accrued during CD8 + T M aging we previously noted several cell surface receptors involved in the regulation of CD8 + T cell traffic and migration [9] and demonstrated the importance of their age-associated expression differences in the context of immune homeostasis [10] . Now, using an unbiased approach based on time series gene set enrichment analyses (GSEA) of aging p14 T M populations [10] , the potential importance of differential "homing receptor" expression is further supported by our identification of the "cell adhesion molecules" module as the top KEGG pathway negatively enriched in old p14 T M (normalized enrichment score: -1.82; p=0.0078; Fig.4A ). For 29/38 genes within this module, we also performed temporal protein expression analyses and demonstrated a significant up-or downregulation by aging CD8 + T M for half of these gene products (15/29; Fig.4A and ref. [9] ). Here, the expression pattern of CD11a/integrin α L caught our attention for several reasons: elevated CD11a expression, similar to CD44, has long been used as a surrogate marker for "antigen-experienced" CD8 + T cells [36] . In combination with CD18/integrin β 2 , CD11a forms the heterodimeric LFA-1 complex that constitutes, together with its endothelial cell-expressed ligands CD54/ICAM1 and CD102/ICAM2, one of the major pathways for leukocyte adhesion. In contrast to CD44, however, CD11a mRNA and protein expression by aging CD8 + T M are subject to a slight yet significant decline (Figs.4A/B, S2 and ref. [9] ). In fact, other components of the LFA-1 pathway exhibited very similar patterns with a progressive decrease of CD8 + T M -expressed CD18, CD102 and in particular CD54 mRNA and/or protein; another LFA-1 ligand, CD50/ICAM5, is not expressed by murine CD8 + T E/M ( Fig.4A/B , S2 and ref. [9] ).
LFA-1 biology has been characterized in great detail [37] and the importance of CD11a for the migration of naïve T cells to peripheral LNs is well-established [38] , yet the precise role of CD11a in the regulation of pathogen-specific T cell immunity remains incompletely defined. In one of the most detailed report to date, Bose et al. found that CD11a-deficiency reduces I o L. monocytogenes-(LM-) specific CD8 + T E responses, skews CD8 + T E phenotypes in favor of "memory precursors", preserves major CD8 + T E functions while stunting ex vivo CTL activity, attenuates the subsequent contraction phase, and, remarkably, enhances II o CD8 + T E expansions by ~1.8-fold following high-dose LM re-challenge [39] . The latter finding, however surprising, is consistent with our "rebound model" of CD8 + T M de-differentiation [9, 10] in that any deficits conveyed by CD11a-deficiency are eclipsed by the advanced maturation stage of CD11a -/-CD8 + T M [39] that is associated with greater recall capacity. Similarly, LFA-1 blockade resulted in a ~2-fold reduction of I o LCMV-specific CD8 + T E expansions (ref. [40] and not shown) but its potential impact in the specific context of CD8 + T M recall responses has not yet been determined. As based on the experience with LFA-1 blockade in transplantation and autoimmunity [41, 42] and considering in particular the lower CD11a and CD54 expression of naïve CD8 + T N [9] , we speculated that CD8 + T M would be overall more resistant to LFA-1 blockade but that declining We conclude that aged CD8 + T M populations rely in part on the LFA-1 system to support their improved recall responses in the periphery.
Like the integrins, and often in conjunction, chemokine receptors sensitize T cells to essential spatiotemporal cues required for the effective orchestration of T cell responses [43] . For example, CD8 + T E and T M subsets can be recruited to reactive LNs by virtue of their CXCR3 expression [44] , and several reports have detailed the importance of CXCR3 for the precise positioning of CD8 + T cells in spleen and LNs, and for the measured rather than accelerated development of I o CD8 + T M populations [45] [46] [47] [48] . However, in regards to the requirement of CD8 + T M -expressed CXCR3 for the regulation of their II o responses, strikingly different conclusions were reached: CXCR3-deficiency either improved II o CD8 + T E expansions [45] , had no effect [46] , or compromised II o CD8 + T E reactivity [48] . virtue of enhanced CXCR3 expression, are poised to effectively harness these interactions.
CD28-but not CD27-dependent co-stimulation preferentially promotes enhanced II o reactivity of aged CD8 + T M .
Recall responses are traditionally regarded as "co-stimulation independent" but more recent work has documented an important role especially for CD28 in the regulation of pathogen-specific II o CD8 + T E immunity [51] . Although our original analysis of genes differentially expressed by young and old CD8 + T M included few members of the major co-stimulatory B7 and TNF superfamilies [9] , the temporal GSEAs conducted here captured many more subtle alterations, including an upregulation of Cd28 by aging p14 T M ( Fig.4A and not shown). A corresponding age-associated augmentation of CD28 protein expression was confirmed and extended here to blood-borne D b NP 396 + and D b GP 33 + CD8 + T M populations, and similar experiments corroborated a particularly prominent increase for CD27 ( Figs.5A & S2) , a co-stimulatory receptor that exhibits some of the most pronounced expression differences between young and old CD8 + T M [9] .
Despite the general importance of the CD27:CD70 co-stimulatory pathway [52] , its contribution to the regulation of LCMV-specific CD8 + T E immunity appears to be more limited. [52, 53] but also on the differentiation stage of specific CD8 + T cells themselves. At the same time, the large increase of CD27 expression by aging CD8 + T M remains unexpectedly inconsequential for the regulation of their II o reactivity.
With regard to the gradual increase of CD28 expression by aging CD8 + T M (Figs.4A, 5A & S2) , earlier work by us and others has already implicated the CD28:CD80/86 pathway in the regulation of LCMV-specific II o CD8 + T E immunity [57, 58] raising the possibility that a more efficient use of these interactions by old suggesting the existence of another CD28 ligand; in contrast, II o CD8 + T E expansions were clearly CD80/86dependent following an LCMV cl13 re-challenge [58] . In agreement with these findings, neither II o nor concurrent I o CD8 + T E responses elicited in the mixed AT/RC Arm system were affected by CD80/86deficiency ( Fig.5E ). Yet a LCMV cl13 infection not only reduced CD8 + T M recall reactivity in general but preferentially comprised the accumulation of aged (6.4-fold) as compared to young (3.6-fold) II o CD8 + T E (Fig.5E ). Together, these results support the notion that CD28-mediated co-stimulation contributes specifically to the improved II o reactivity of aged CD8 + T M .
Role of CD40L and CD4 + T cells in the differential regulation of young and old II o CD8 + T E responses.
In extension of our investigation into co-stimulatory pathways above, we also evaluated the potential involvement of CD40L:CD40 interactions in the regulation of II o CD8 + T E immunity, experiments prompted by our observation that aged CD8 + T M synthesize larger amounts of CD40L upon re-stimulation [9] . Although CD8 + T cell-produced CD40L appears dispensable for I o CD8 + T E responses [60] , it readily promotes DC activation, B cell proliferation and antibody production (activities usually associated with CD4 + "helper" T cells) [61] , and may boost II o CD8 + T E immunity under conditions of limited inflammation [62] . Similarly, our previous work has documented that CD40L blockade administered within the first week of acute LCMV Arm infection does not impinge on I o CD8 + T E responses but affects subsequent CD8 + T M development as revealed by impaired II o in vitro CTL activity [63] . While these results point towards a more limited and context-dependent role for CD8 + T cell-produced CD40L, any interpretation of outcomes observed after anti-CD40L treatment has to consider that it targets both CD4 + and CD8 + T cell subsets.
In the mixed AT/RC Arm setting employed here, acute CD40L blockade did not compromise either I o (not shown) or II o CD8 + T E responses (Fig.5C ), observations that are also consistent with the finding that provision of additional CD4 + T cell help did not embellish either I o or II o p14 T E expansions in the wake of an LCMV Arm infection [64] . Yet the situation was reportedly different in the chronic LCMV model:
supplementary CD4 + T cell help increased II o but not I o p14 T E responses, and the effect was abolished by CD40L blockade supporting the conclusion that CD8 + T M are more reliant than CD8 + T N on CD40L-mediated CD4 + T cell help [64] . In the experiments shown in Fig.5F , we quantified CD8 where CD4 + T cell depletion greatly reduced I o CD8 + T E responses [65] . The complementary observation that CD4 + T cell depletion in the context of an LM re-challenge also curtailed II o CD8 + T E expansions, and that this effect became more pronounced with advancing age [65] further indicates that aging CD8 + T M gradually reestablish a reliance on CD4 + T cell help akin to that exhibited by CD8 + T N .
Enforced SAP expression constrains II o CD8 + T E expansions.
The expression patterns of CD2/SLAM family genes and proteins provide yet another example for the converging temporal regulation of CD8 + T M properties within a defined molecular family: with the exception of stable SLAMF3/Ly9 levels, both mRNA and protein expression of other CD2/SLAM family members were progressively downmodulated in aging CD8 + T M populations [9] . The functional relevance of these phenotypic changes, however, is difficult to predict since they pertain to both activating and inhibitory receptors, and studies with various blocking/activating antibodies and SLAM receptor-deficient mouse strains have generated at times conflicting results [66] . Even so, since all signaling events transduced by T cell-expressed SLAM receptors operate through the same small adaptor SAP (SLAM-associated protein) [66] , a slight decline of Sh2d1a message in aging CD8 + T M was noteworthy [9] in light of earlier work with
SAP -/mice that demonstrated an increase of I o virus-specific CD8 + T E expansions and associated virus
control [66] . The precise cause for this enhancement remains to be determined but a contributing if not essential factor is likely an impairment of activation-induced cell death (AICD) in the SAP -/mice [67] . In our experiments, however, the decrease of Sh2d1a in aging CD8 + T M was not accompanied by a corresponding reduction of SAP protein expression [9] , and eight days after mixed AT/RC Arm, the activation-induced increase of SAP was not significantly different between young and old II o CD8 + T E (not shown).
Despite these caveats, we chose to explore the additional possibility of differential SAP induction specifically in the earliest phase of the II o response. To this end, we employed the "p14 chimera" model and compared the initial recall response of young and aged p14 T M by CFSE dilution both in vivo and in vitro.
Although we observed similar proliferation patterns for all II o p14 T E populations (Fig.6A ), more detailed analyses of the in vitro studies suggested that aged p14 T M might start to divide a little earlier (i.e., exhibiting a ~1.4-fold higher division indices, not shown) yet the identical proliferation indices of young and old II o p14 T E (Fig.6A ) are consistent with our earlier conclusion about the comparable antigen-driven proliferation of young and old II o NP 396 -specific CD8 + T E in the periphery [9] . Importantly though, the better survival of aged II o CD8 + T E in our in vivo model [9] corresponded to higher numbers of old II o p14 T E surviving in the in vitro culture system (Fig.6A ) supporting the general utility of the latter experimental approach. We then proceeded with the quantification of SAP expression as a function of in vitro proliferation and found that the early II o effector phase of young but not old p14 T M was accompanied by a significant elevation of SAP levels (Fig.6A ). Thus, the increased in vitro accumulation of aged II o p14 T E correlates with their lower SAP expression which is consistent with the notion of impaired AICD in the absence of SAP [67] .
To formally evaluate the hypothesis that the amount of induced SAP expression determines the recall reactivity of II o CD8 + T E populations, we generated retroviral p14 chimeras that overexpress SAP selectively in subpopulations of p14 T E/M as detailed in (CD48) density and, importantly, the level of SAP expression itself [68] . Although those results correlated high SAP expression with activation rather than inhibition [68] , an increase of CD244:CD48 interactions could nevertheless convey inhibitory signals even in the presence of elevated SAP expression [69] .
Furthermore, in the chronic LCMV model, CD244 was assigned a predominantly inhibitory function as based on enhanced NK cell activity in CD244 -/mice as well as the greater II o reactivity of CD244 -/-p14 T M in the
DISCUSSION
As a widely used preclinical experimental system, the LCMV model has proved extraordinarily helpful in shaping our understanding of protective T cell memory as well as its limitations in the context of persistent viral infections [2, 72, 73] . Here, we used the LCMV model to interrogate over a dozen molecular pathways for their contribution to the embellishment of CD8 + T M recall responses, and our results are noteworthy for the identification of 1., diverse molecular interactions that specifically promote the greater II o CD8 + T E expansions of aged CD8 + T M populations; 2., the distinct outcomes observed after acute vs. chronic LCMV re-challenge; and 3., the receptors/ligands that, against expectation, apparently did not participate in the regulation of II o CD8 + T E immunity.
To explore the possibility that improved recall responses of aged CD8 + T M emerge as the net result of multiple disparate molecular interactions, we selected a diverse set of pathways comprising cytokine signaling, T cell trafficking, co-stimulation and -inhibition, and effector functionalities as based on the longterm expression kinetics of the respective CD8 + T M -expressed receptors/ligands (the relative robustness of these temporal expression patterns is now supported by an extension of our earlier analyses to blood-borne aging antiviral CD8 + T M populations, and to subsets with different epitope specificities and TCR affinities/avidities [9] ). Our results demonstrate that IL-4-, LFA-1-, CXCR3-and CD28-dependent Furthermore, the above interactions are for the most part of greater importance to the regulation of II o CD8 + T E immunity in response to a chronic rather than acute viral challenge. Recent work supports the notion that the eventual or at least partial control of chronic viral infections relies on a multiplicity of molecular pathways that are often dispensable for clearance of acute virus infections [74] . Our findings extend this concept to the context of II o CD8 + T E responses by documenting that CD8 + T M , far from being "co-stimulation independent", also require the productive engagement of diverse molecular interactions to unfold their full recall potential when confronted with a chronic virus challenge. A further elucidation of these phenomena might very well help to establish an adjusted perspective onto one of the central tenets of T cell memory, namely its presumed imperviousness to the modulation by biochemical pathways commonly referred to as "signal 2 & signal 3". In fact, the "rebound model" [9] , together with the present report, suggests that aging CD8 + T M become increasingly reliant on the very same "signal 2 & signal 3" interactions that, dependent on the experimental system, also control I o CD8 + T E differentiation.
Two pathways interrogated in the present study were found to be of preferential importance to the regulation of young rather than old II o CD8 + T E responses. Here, the greater dependence of young CD8 + T M recall responses on CD4 + T cell help and CD40L-mediated interactions in the chronic LCMV system is essentially consistent with the "rebound model", but the enhanced reliance of young CD8 + T M on non-CD8 + T M -produced IFNγ, despite reduced CD119/IFNγR1 expression and sensitivity, was unexpected. IFNγ can exert both stimulatory and inhibitory effects on CD8 + T E populations [29, 75] , and the specific balance achieved between these opposing signals may be distinct for young and old CD8 + T M , perhaps as a result of differential IFNγR2 induction [76] , but ultimately the reasons for the greater role of host IFNγ in control of young II o CD8 + T E immunity remain unclear. We also found that several other cytokine signaling and costimulatory pathways (IL-6, IL-7, IL-15, TSLP, TGFβ, CD27:CD70) appeared to have at best a minor impact on the regulation of II o CD8 + T E responses. While these results underscore the obvious fact that promising clues gleaned from a comprehensive set of databases [9] need not necessarily translate into biologically relevant differences within a given model system, they neither rule out potential redundancies not investigated in the present study nor the possibility that these as well as additional pathways may be operative in the context of other experimental and naturally occurring scenarios. Therefore, in as much as the "rebound model" of extended CD8 + T M maturation applies to pathogen infections in general, the progressive "de-differentiation" of aging CD8 + T M , especially given the "programmed" nature of this process [9] , may allow them to brace for more effective recall responses under a greater variety of productive pathogen re-encounters. At the same time, the multitude of diverse molecular pathways involved in shaping improved clinical outcomes also provides an abundance of different targets for potential therapeutic interventions.
MATERIALS AND METHODS
Ethics statement
All procedures involving laboratory animals were conducted in accordance with recommendations in to these criteria, up to ~30% of aging mice were excluded from the study.
Tissue processing, cell purification and adoptive transfers (AT)
Lymphocytes were obtained from blood, spleen and LNs according to standard procedures [78] .
Enrichment of splenic T cells was performed with magnetic beads using variations and adaptations of established protocols [9] and reagents purchased from StemCell Technologies, Miltenyi Biotec and Invitrogen/Caltag (Table S1) 1A-D, 2C-E, 3B-D, 4C/E & 5B-F) . For construction of p14 chimeras [9] , CD8 + T cells were enriched from spleens of naïve CD90.1 + p14 mice by negative selection, and 5x10 4 purified p14 cells were transferred i.v. into B6 recipients prior to LCMV infection 2-24h later (Figs.2B, 3A, 4A, 6A & S1) . In vivo proliferation of II o p14T E was assessed by AT of 10 6 young or old CFSE-labeled p14 T M into B6 recipients and LCMV Arm challenge as detailed in ref [9] ; analyses were then conducted with II o p14T E recovered from recipient spleens 64h later (Fig.6A ).
Stimulation cultures
Splenic single cell suspensions prepared from young and old LCMV-immune p14 chimeras were cultured for 15min in complete RPMI with graded dosages of recombinant cytokines (murine IL-4, IL-6, IL-10, IFNγ; Peprotech) prior to fixation with PFA buffer, processing and combined CD90.1 and intracellular pSTAT staining (Figs.2B & 3A) . For in vitro proliferation and survival assays, lympholyte-purified PBMC from young and old LCMV-immune p14 chimeras were labeled with CFSE, adjusted to contain the same number of p14 T M , and cultured for 72h with T cell-depleted, LCMV-GP 33-41 peptide-coated B6 spleen cells;
numbers of surviving p14 T cells were subsequently calculated using Countess (Invitrogen) or Vi-Cell (Beckmann Coulter) automated cell counters (Fig.6A ).
Flow cytometry
All reagents and materials used for analytical flow cytometry are summarized in Table S1 , and our basic staining protocols are described and/or referenced in ref. [9] . Detection of phosphorylated STAT proteins ( Figs.2B & 3A) was performed using a methanol-based cell permeabilization as described [79] . All samples were acquired on FACSCalibur, LSR II (BDBiosciences) or Cyan (Beckman Coulter) flow cytometers and analyzed with DIVA (BDBiosciences) and/or FlowJo (TreeStar) software; visualization of in vivo and in vitro T cell proliferation by step-wise dilution of CFSE and calculation proliferation and division indices was performed using the FlowJo "proliferation platform" (Fig.6A) .
Microarray analyses
Details for microarray analyses of highly purified p14 T E/M populations and time series GSEAs (Figs.4A & S1) are found in refs. [9, 10] . corresponding control antibodies: dosages commensurate to experimental antibodies); CD4 + T cell depletion was achieved by i.p. injection of 200µg GK1.5 antibody on days -1 and +1 in relation to AT/RC [80] . Further details about all in vivo antibodies are provided in Table S1 .
In vivo antibody treatment
Retroviral transductions, chimera construction and transduced p14 T M purification
Murine Sh2d1a (SAP) cDNA was purchased from Open Biosystems (clone ID 1400188) and subcloned into a murine stem cell virus-(MSCV-) based retroviral pMiG vector that contains GFP as a reporter (gift from P. Marrack). To generate retroviruses, pMiG-empty or pMiG-SAP plasmids were co-transfected with PsiEco helper plasmid into Phoenix 293T cells using Fugene 6 (Roche) according to standard procedures [79] . After 48h, retroviral supernatants were harvested and spin-transductions of in vivo activated p14 splenocytes (naïve p14 mice infected with 2x10 6 pfu LCMV Arm i.v. 24h earlier) were performed for 90min at 32°C in the presence of 8µg/mL polybrene, 10mM HEPES and 10µg/mL recombinant hIL-2. Transduced p14 splenocytes were transferred "blind" into naïve B6 mice that were subsequently infected with 2x10 5 pfu LCMV Arm i.p. (Fig.6B) , and effective transduction levels were verified in blood-borne p14 T E 8 days later (Fig.6C ). For subsequent AT/RC experiments, transduced p14 T M (CD4 -B220 -CD90.1 + GFP + ) were purified from spleens using a Coulter Moflo XDP cell sorter.
Statistical analyses
Data handling, analysis and graphic representation was performed using Prism 6.0c (GraphPad Software). All data summarized in bar and line diagrams are expressed as mean ±1 standard error (SEM),
and asterisks indicate statistical differences calculated by Student's t-test, or one-way ANOVA with Dunnett's multiple comparisons test, and adopt the following convention: *: p<0.05, **: p<0.01 and ***:
p<0.001. Figs.2A/B, 3A, S2 and/or refs. [9, 10] . 
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